Risk factors for invasive mold infections following allogeneic hematopoietic stem cell transplantation: A single center study of 190 recipients

Scandinavian Journal of Infectious Diseases

Volumn 44, Issue 2, 2012, Pages 100-107

  Li, Lili ^a   Wang, Jianmin ^a   Zhang, Weiping ^a   Yang, Jianmin ^a   Chen, Li ^a   Lv, Shuqing ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Corticosteroid therapy; HSCT; Mold infection; Risk factors

Indexed keywords

BUSULFAN; CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; VANCOMYCIN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT RECIPIENT; HUMAN; INCIDENCE; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOULD; NEUTROPENIA; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SYSTEMIC MYCOSIS;

ADRENAL CORTEX HORMONES; ADULT; ANTIFUNGAL AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MULTIVARIATE ANALYSIS; MYCOSES; NEUTROPENIA; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84862930464     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2011.623311     Document Type: Article

References (28)

1. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100: 4358-66. (Pubitemid 35429674)
2. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-17. (Pubitemid 34229758)
3. Rabagliati BR, Fuentes LG, Guzm án DA, Orellana UE, Oporto CJ, Aedo CI, et al. Invasive fungal disease in hematooncological and hematopoietic stem cell transplantation patients from Hospital Clinico Universidad Cat ó lica, Santiago- Chile using revised EORTC/MSG diagnostic criteria. Rev Chilena Infectol 2009;26:212-9.
4. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008;47:1041-50.
5. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175:1459-66. (Pubitemid 27225051)
6. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001 - 2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010;50:1091-100.
7. Mikulska M, Raiola AM, Bruno B, Furfaro E, Van Lint MT, Bregante S, et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 2009;44:361-70.
8. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18:295-304.
9. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-17. (Pubitemid 10036817)
10. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defi ning opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14. (Pubitemid 33152659)
11. Horn DL, Fishman JA, Steinbach WJ, Anaissie EJ, Marr KA, Olyaei AJ, et al. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 2007;59:407-14. (Pubitemid 350186332)
12. Post MJ, Lass-Floerl C, Gastl G, Nachbaur D. Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis 2007;9:189-95. (Pubitemid 47231210)
13. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009;48: 265-73.
14. Morgan J, Wannemuehler KA, Marr KA, Hadley S, Kontoyiannis DP, Walsh TJ, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005;43:S49 - 58. (Pubitemid 41038548)
15. Waldorf AR, Levitz SM, Diamond RD. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J Infect Dis 1984;150:752-60. (Pubitemid 15200085)
16. Roilides E, Uhling K, Venzon D, Pizzo PA, Walsh TJ. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993;61:4870-7.
17. Ng TT, Robson GD, Denning DW. Hydrocortisone- enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 1994;140:2475-9. (Pubitemid 24297055)
18. Sainz J, Hassan L, Perez E, Romero A, Moratalla A, Ló p ez- Fern á ndez E, et al. Interleukin-10 promoter polymorphism as risk factor to develop invasive pulmonary aspergillosis. Immunol Lett 2007;109:76-82. (Pubitemid 46371411)
19. Sainz J, Pé rez E, Hassan L, Moratalla A, Romero A, Collado MD, et al. Variable number of tandem repeats of TNF receptor type 2 promoter as genetic biomarker of susceptibility to develop invasive pulmonary aspergillosis. Hum Immunol 2007;68:41-50. (Pubitemid 46026885)
20. Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, Janer M, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008;359:1766-77.
21. Rosenhagen M, Feldhues R, Schmidt J, Hoppe-Tichy T, Geiss HK. A risk profi le for invasive aspergillosis in liver transplant recipients. Infection 2009;37:313-9.
22. Laursen AL, Mogensen SC, Andersen HM, Andersen PL, Ellermann-Eriksen S. The impact of CMV on the respiratory burst of macrophages in response to Pneumocystis carinii. Clin Exp Immunol 2001;123:239-46. (Pubitemid 32174775)
23. Baron M, Davignon JL. Inhibition of IFN-gamma-induced STAT1 tyrosine phosphorylation by human CMV is mediated by SHP21. J Immunol 2008;181:5530-6.
24. Moutaftsi M, Mehl AM, Borysiewicz LK, Tabi Z. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood 2002;99:2913-21. (Pubitemid 34525381)
25. Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparrelid E, Aschan J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006;91:78-83. (Pubitemid 43235389)
26. Larsson K, Aschan J, Remberger M, Ringd é n O, Winiarski J, Ljungman P. Reduced risk for extensive chronic graftversus- host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus. Transplantation 2004;77:526-31. (Pubitemid 38282806)
27. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007;44:531-40. (Pubitemid 46233255)
28. Baddley JW, Andes DR, Marr KA, Kontoyiannis DP, Alexander BD, Kauffman CA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010;50:1559-67